Crysvita (Burosumab)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Crysvita is a medication used to help people with certain hereditary conditions that make it hard for their bodies to absorb phosphate, an essential nutrient. It works by blocking a protein called FGF23, which normally helps control phosphate levels in the body. By stopping FGF23, Crysvita allows the body to keep more of the phosphate it needs. This is especially helpful for individuals with a condition called X-linked hypophosphatemia (XLH), where phosphate absorption is a problem. Crysvita has been approved by the FDA for use in both adults and children over six months old who have XLH.
Fact Table
Formula
C6444H9948N1712O2016S50
License
US FDA, EMA
Bioavailability
62% (subcutaneous)
Legal status
Prescription only (Rx)
Chemical Name
Burosumab (human IgG1 kappa monoclonal antibody)
Elimination half-life
19 days
Dosage (Strength)
10 mg/mL, 20 mg/mL, 30 mg/mL solution for injection
Pregnancy
Consult a doctor (Category Not Assigned)
Brands
Crysvita
Protein binding
N/A (monoclonal antibody)
PubChem CID
122881780
MedlinePlus
a618064
ChEBI
N/A
ATC code
M05BX05
DrugBank
DB13975
KEGG
D11015
Routes of administration
Subcutaneous injection
Directions
For adults, the recommended starting dose is once every four weeks. For children, the dosing frequency is typically once every two weeks. The amount of Crysvita given is based on the person’s body weight, with the specific dose determined by a healthcare provider. Patients should be aware that more than one injection may be needed, depending on their individual treatment plan.
Ingredients
The active ingredient in Crysvita is Burosumab.
Contraindications
Do not use Crysvita if any of the following apply:
- You are taking oral phosphate supplements or active vitamin D medications (like calcitriol, paricalcitol, doxercalciferol, or calcifediol), as this can raise your phosphate levels too high.
- Your serum phosphorus levels are already normal or above normal for your age.
- You have severe kidney problems or are at the end stage of kidney disease.
Cautions
- Before starting treatment with Crysvita, be sure to inform your healthcare provider about the following:
- Any medical conditions you currently have
- Any allergies
- All medications you are currently taking
- Whether you are pregnant or breastfeeding
- If you experience allergic reactions such as rash or hives while taking Crysvita, stop the treatment immediately and seek medical care.
- Crysvita can cause your phosphorus levels to rise above normal, which might lead to kidney issues like nephrocalcinosis. Your doctor may adjust your dose or pause your treatment depending on your blood phosphorus levels.
- Crysvita injections might cause reactions at the site of injection. If severe reactions occur, stop the treatment and consult your healthcare provider for appropriate care.
Side Effects
Common side effects of the Crysvita injection include fever, cough, vomiting, and pain in the extremities. Children treated with Crysvita may also experience injection site reactions, which include redness, pain, and swelling, as well as headaches and dental issues like tooth abscesses and caries. These side effects are generally a response to the medication's action on the body.
Serious side effects may include hypersensitivity reactions like rash and injection site urticaria, as well as complications related to high phosphorus levels, potentially leading to nephrocalcinosis. If you notice severe skin reactions, severe discomfort around the injection site, or signs suggesting changes in phosphate levels (such as unusual tiredness or joint pain), contact your healthcare provider immediately.
References
- Crysvita (Burosumab) Product Monograph. Bedminster, NJ: Kyowa Kirin, Inc.; 2020.
- Crysvita (Burosumab) Drug Label Information. Bedminster, NJ: Kyowa Kirin, Inc.; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14971
-
Product Reviews
